Description:

Does your potential therapeutic stand out?

Please join us for the fourth INVOForward seminar during which Marta New (CEO, Radyus Research) will discuss key considerations for differentiating your potential therapeutic and assessing product-market fit. Dr. New will explore critical topics such as identifying and thinking like your end customers (including both pharmaceutical companies and patients). She will also highlight the importance of establishing novelty for a given therapeutic target and/or approach. Dr. New will offer practical insight into performing a competitive analysis and assessing the value proposition of your therapeutic. She will also underscore the importance of telling a good story and share key ingredients for crafting a compelling narrative.

This seminar is part of the INVOForward Therapeutics lecture series focused on helping Northwestern researchers gain insight into how to build a compelling therapeutic data package. While the INVOForward mentorship program has four select faculty-led teams participating, the lectures are open to Northwestern Faculty, Post-docs, Staff and Students.

Please register in advance.

Other INVOForward lectures may be found here.

OUR SPEAKER

Marta New, Ph.D., M.B.A.

Marta is the founding CEO of Radyus Research, a CRO based in Atlanta, GA. Radyus is focused on all aspects of preclinical therapeutics development, from strategic planning to experimental execution and regulatory filings. Before starting Radyus, Marta was the co-founding Partner at Agent Capital, a life sciences-focused venture capital firm based in Cambridge, MA. While at Agent, Marta led multiple venture capital investments in oncology, immunology and rare disease areas including Orchard Therapeutics (NASDAQ:ORTX), Precision Biosciences (NASDAQ:DITL), Pliant Therapeutics and Verge Genomics, among others. Prior to Agent Capital, Marta was a Principal investor at Baxalta Ventures, the corporate venture capital arm of Baxalta in Cambridge MA, where she led multiple venture capital investments and served as a board observer for Gadeta BV (acquired by Kite/Gilead, 2018), Syntimmune (acq. by Alexion, 2018), and Vitesse Biologics (early stage accelerator funded by Baxalta, Mayo Clinic and Velocity Pharmaceutical Development).

Marta started her investment career at Baxter Ventures, the corporate venture capital arm of Baxter in Chicago, IL, transitioning from the Global Renal Marketing franchise, where she was the commercial lead for multiple new products for the Chinese and European markets. She joined Baxter from Northwestern University’s Innovation and New Ventures Office where she was responsible for licensing negotiations, commercial assessment of patents, and industry alliance management.

Marta received her PhD from the University of Illinois at Chicago in microbiology and immunology and completed her post-doctoral training at Northwestern University. She also received an MBA from Northwestern University Kellogg School of Management in Chicago, IL.

INVOForward Therapeutics is a 7-week Northwestern mentorship program designed to accelerate biomedical commercialization at the university.

If you have any questions, please email INVOForward@northwestern.edu